Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 128 participants.

Also called NCT06359782

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06359782
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06359782. Randomized; quadruple masking; primary purpose treatment. Start 2024-11-04 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
Acronym
CIAO@SAH
Condition
Subarachnoid Hemorrhage, Aneurysmal
Intervention (Drug)
C1 Esterase Inhibitor Injection [Cinryze]
Intervention (Drug)
Placebo
Lead sponsor
Haaglanden Medical Centre (class: other)
Collaborator
Leiden University Medical Center (class: other)
Collaborator
Takeda (class: industry)

Record details

Record id
cardio:ct-nct06359782
Content hash
c5f66b7464caae85256d520c83ad1f32f8be2dab799cf685d44335d9d31ec23f